These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35616272)

  • 1. Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat.
    Gu M; Ruan X; Li Y; Li T; Yin C; Mueck AO
    Gynecol Endocrinol; 2022 Jul; 38(7):598-602. PubMed ID: 35616272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of orlistat during individualized comprehensive life-style intervention on visceral fat in overweight or obese PCOS patients.
    Min M; Ruan X; Wang H; Cheng J; Luo S; Xu Z; Li M; Mueck AO
    Gynecol Endocrinol; 2022 Aug; 38(8):676-680. PubMed ID: 35723579
    [No Abstract]   [Full Text] [Related]  

  • 3. Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome.
    Cinar N; Harmanci A; Bayraktar M; Yildiz BO
    Clin Endocrinol (Oxf); 2013 Mar; 78(3):379-84. PubMed ID: 22509734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
    Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO
    Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
    Tfayli H; Ulnach JW; Lee S; Sutton-Tyrrell K; Arslanian S
    J Clin Endocrinol Metab; 2011 May; 96(5):1311-9. PubMed ID: 21325466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study.
    Li L; Zhang R; Zeng J; Ke H; Peng X; Huang L; Zhang H; Chen Z; Li TT; Tan Q; Yang Y; Li X; Li X
    BMC Womens Health; 2020 Feb; 20(1):39. PubMed ID: 32106860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
    Harmanci A; Cinar N; Bayraktar M; Yildiz BO
    Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial.
    Moro F; Morciano A; Tropea A; Sagnella F; Palla C; Scarinci E; Ciardulli A; Martinez D; Familiari A; Liuzzo G; Tritarelli A; Cosentino N; Niccoli G; Crea F; Lanzone A; Apa R
    Reprod Sci; 2013 Dec; 20(12):1508-17. PubMed ID: 23690338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
    Ruan X; Song J; Gu M; Wang L; Wang H; Mueck AO
    Arch Gynecol Obstet; 2018 Jun; 297(6):1557-1563. PubMed ID: 29602978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome.
    Li J; Ren J; Sun W
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():13-21. PubMed ID: 27923166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up.
    Yildizhan R; Gokce AI; Yildizhan B; Cim N
    Gynecol Endocrinol; 2015 May; 31(5):396-400. PubMed ID: 25739031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin.
    Sun X; Wu X; Zhou Y; Yu X; Zhang W
    Med Sci Monit; 2015 Aug; 21():2547-52. PubMed ID: 26314870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
    Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N
    Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral contraceptives plus orlistat in patients with polycystic ovary syndrome and overweight/obesity: A meta-analysis.
    Chen Z; Cai Z
    J Obstet Gynaecol Res; 2022 Jun; 48(6):1399-1408. PubMed ID: 35302695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chlormadinone acetate versus drospirenone-containing oral contraceptives on the endocrinal features of women with polycystic ovary syndrome: Systematic review and meta-analysis of randomized clinical trials.
    Menshawy A; Ismail A; Abdel-Maboud M; El-Din AA; Elgebaly A; Gadelkarim M; Bahbah EI; Abdelghany MF; Samy A; Abbas AM
    J Gynecol Obstet Hum Reprod; 2019 Nov; 48(9):763-770. PubMed ID: 30940512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis.
    Wang A; Mo T; Li Q; Shen C; Liu M
    Endocrine; 2019 May; 64(2):220-232. PubMed ID: 30911997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
    Filippatos TD; Kiortsis DN; Liberopoulos EN; Georgoula M; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2005 Dec; 21(12):1997-2006. PubMed ID: 16368051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials.
    Abdel-Maboud M; Menshawy A; Hasabo EA; Abdelraoof MI; Alshandidy M; Eid M; Menshawy E; Outani O; Menshawy A
    PLoS One; 2021; 16(7):e0254412. PubMed ID: 34280195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.
    Guido M; Romualdi D; Giuliani M; Suriano R; Selvaggi L; Apa R; Lanzone A
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2817-23. PubMed ID: 15181063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.